<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666978</url>
  </required_header>
  <id_info>
    <org_study_id>10332</org_study_id>
    <secondary_id>R01CA091912</secondary_id>
    <secondary_id>KUMC-HSC-10332</secondary_id>
    <secondary_id>KUMC-070313</secondary_id>
    <nct_id>NCT00666978</nct_id>
  </id_info>
  <brief_title>Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking</brief_title>
  <official_title>Enhancing Tobacco Use Treatment for African American Light Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisa Sanderson Cox, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may
      help African-American smokers stop smoking. It is not yet known whether health education
      counseling is more effective with or without bupropion in helping African Americans stop
      smoking.

      PURPOSE: This clinical trial is studying health education counseling and bupropion to see how
      well they work compared with a placebo and health education counseling in helping African
      Americans smokers stop smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the efficacy of bupropion hydrochloride and health education counseling vs
           placebo and health education counseling for smoking cessation among African Americans
           who are light smokers.

      Secondary

        -  To characterize CYP2A6 activity in African Americans who are light smokers by evaluating
           phenotype (3'hydroxycotinine/cotinine ratio [3HC/COT]) and CYP2A6 genotype.

        -  To evaluate the relationship between CYP2A6 activity and smoking cessation outcomes.

        -  To evaluate CYP2A6 genetic polymorphisms associated with nicotine and cotinine
           metabolism in African Americans who are light smokers.

        -  To measure baseline cotinine and metabolite levels to evaluate the nicotine metabolism
           phenotype of 3HC/COT.

        -  To evaluate the relationship between nicotine metabolism phenotype of 3HC/COT and
           smoking cessation outcomes.

        -  To evaluate CYP2A6 genotype as a predictor of smoking cessation outcomes.

      Tertiary

        -  To characterize CYP2B6 activity in African Americans who are light smokers by evaluating
           phenotype and CYP2B6 genotype.

        -  To evaluate the relationship between CYP2B6 activity and smoking cessation outcomes.

        -  To measure steady state bupropion hydrochloride and metabolite levels to identify a
           bupropion metabolism phenotype.

        -  To evaluate the relationship between bupropion hydrochloride metabolism phenotype and
           smoking cessation outcomes.

        -  To evaluate the relationship between CYP2B6 genetic polymorphisms (genotype) and blood
           levels of bupropion hydrochloride and active metabolites (phenotype).

        -  To determine the effects of CYP2B6 genotype as predictors of smoking cessation outcomes.

      OUTLINE: Participants are randomized to one of two arms.

        -  Arm I: Participants receive oral bupropion hydrochloride once or twice daily in weeks
           0-6. Participants also undergo 6 sessions of health education counseling conducted in
           person during clinic visits in weeks 0, 3, and 7 and via telephone in weeks 1, 5, and
           16. The health education counseling sessions include providing information about the
           risks of continued smoking and the benefits of quitting, developing a quit plan,
           outlining a concrete quit day preparation plan, discussing strategies for successful
           quitting, building social support, reducing stress, recognizing and managing withdrawal
           and craving, overcoming barriers to abstinence, and using medication for smoking
           cessation. Participants receive Kick It at Swope: Stop Smoking Guide, a
           culturally-sensitive smoking cessation guide, to review with their study counselor
           during the first counseling session.

        -  Arm II: Participants receive an oral placebo once or twice daily in weeks 0-6.
           Participants also undergo health education counseling as in arm I.

      Participants complete baseline questionnaires about demographics, smoking history, and
      psychometrics, including the following: racial identity, depressive symptoms, alcohol use,
      stress, smoking consequences, social support, environmental influences of smoking, adherence
      to study medication, nicotine withdrawal, craving, and mood.

      Participants undergo serum sample collection in weeks 0 and 3. To standardize the time since
      the last cigarette, participants are asked to smoke one cigarette prior to serum sample
      collection in week 0. Samples are analyzed for nicotine metabolism phenotype and bupropion
      hydrochloride metabolism phenotype by liquid chromatography and mass spectrometry and CYP2A6
      and CYP2B6 genotype by polymerase chain reaction and polymorphism analysis. Participants who
      self-report abstinence also undergo saliva sample collection in weeks 7 and 26 to measure
      cotinine levels to verify smoking status.

      After completion of study intervention, participants are followed at 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Salivary cotinine-verified smoking abstinence at 6 months. A cut point of 15 ng/ml was used to differentiate smokers from nonsmokers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Slow and Fast Metabolizers by Metabolite Ratio</measure>
    <time_frame>Weeks 0</time_frame>
    <description>Analyzed CYP2A6 by activity, called the nicotine metabolite ratio using a split between slow and fast metabolism at 0.31.
The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.
Blood samples were collected for 3HC/COT ratio at Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants for Each CYP2B6 Allele</measure>
    <time_frame>Week 3</time_frame>
    <description>We genotyped CYP2B6 in 268 from the Bupropion arm as this polymorphism is related to bupropion metabolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Slow and Fast Metabolizers by Genotype</measure>
    <time_frame>Week 0</time_frame>
    <description>Analyzed CYP2A6 by genotype. The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.
Slow metabolizers have any reduction or loss of function variant. Fast metabolizers are *1/*1 genotype by exclusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Liver Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Bupropion Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergo smoking cessation intervention and take bupropion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Education Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive counseling intervention and take placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>smoking cessation intervention</intervention_name>
    <arm_group_label>Bupropion Arm</arm_group_label>
    <arm_group_label>Health Education Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion hydrochloride</intervention_name>
    <arm_group_label>Bupropion Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>Bupropion Arm</arm_group_label>
    <arm_group_label>Health Education Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <arm_group_label>Bupropion Arm</arm_group_label>
    <arm_group_label>Health Education Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>counseling intervention</intervention_name>
    <arm_group_label>Bupropion Arm</arm_group_label>
    <arm_group_label>Health Education Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>educational intervention</intervention_name>
    <arm_group_label>Bupropion Arm</arm_group_label>
    <arm_group_label>Health Education Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
    <arm_group_label>Bupropion Arm</arm_group_label>
    <arm_group_label>Health Education Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  African American who has smoked ≤ 10 cigarettes per day for ≥ 2 years AND has smoked
             for ≥ 25 days within the past month

               -  Not a heavy smoker

               -  No other forms of tobacco within the past 30 days

          -  Must be interested in stopping smoking

          -  No other smoker in the household enrolled in this study

        PATIENT CHARACTERISTICS:

          -  Has a home address and a functioning telephone number

          -  Not planning to move from the Kansas City metro area within the next 12 months

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No alcohol or substance abuse within the past year

          -  Not currently drinking ≥ 14 alcoholic drinks per week

          -  No binge drinking (5 or more drinks on one occasion) on at least two occasions within
             the past month

          -  No history of seizures or head trauma

          -  No history of bulimia or anorexia nervosa

          -  No myocardial infarction within the past 30 days

          -  No reported use of opiates, cocaine, or stimulants

          -  No diabetes requiring oral hypoglycemics or insulin

        PRIOR CONCURRENT THERAPY:

          -  More than 30 days since prior nicotine replacement therapy, fluoxetine, clonidine,
             buspirone, or doxepin

          -  No other concurrent medication that contains bupropion hydrochloride

          -  No concurrent psychoactive medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa S. Cox, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swope Health Central</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>June 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2017</results_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Lisa Sanderson Cox, PhD</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>adult primary liver cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>adult acute myeloid leukemia</keyword>
  <keyword>tobacco use disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupropion Arm</title>
          <description>270 African American adults received bupropion (150mg bid) for 7 weeks in addition to health education counseling.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>270 African American adults received placebo for 7 weeks in addition to health education counseling.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="270"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupropion Arm</title>
          <description>270 African American adults received bupropion (150mg bid) for 7 weeks in addition to health education counseling.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>270 African American adults received placebo for 7 weeks in addition to health education counseling.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="270"/>
            <count group_id="B2" value="270"/>
            <count group_id="B3" value="540"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.8" spread="11.1"/>
                    <measurement group_id="B2" value="46.2" spread="11.5"/>
                    <measurement group_id="B3" value="46.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="540"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Married or living with partner</title>
          <population>One participant refused the question.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="269"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="539"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Monthly family income &lt;$1800</title>
          <population>6 participants refused the question.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="267"/>
                    <count group_id="B3" value="534"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education &gt; or = high school</title>
          <population>One participant refused the question.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="269"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="539"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196.1" spread="51.8"/>
                    <measurement group_id="B2" value="194.8" spread="54.0"/>
                    <measurement group_id="B3" value="195.5" spread="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <population>One participant refused to collect weight.</population>
          <units>kg/m 2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="269"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="539"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.1" spread="7.6"/>
                    <measurement group_id="B2" value="31.1" spread="8.1"/>
                    <measurement group_id="B3" value="31.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depression(CESD-10) score</title>
          <description>CESD-10 assessed distress associated with depressive symptoms: possible total score ranges from 0 to 30, with a score of 10 or greater reflecting clinically significant depression.</description>
          <population>One participant refused the questions.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="269"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="539"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="4.9"/>
                    <measurement group_id="B2" value="8.2" spread="5.5"/>
                    <measurement group_id="B3" value="7.7" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stress (PSS-4)</title>
          <description>PSS-4 assessed self-appraised global stress: possible total score ranges from 0 to 16. Higher scores indicate more stress.</description>
          <population>One participant refused to answer.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="269"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="539"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="3.1"/>
                    <measurement group_id="B2" value="5.5" spread="3.3"/>
                    <measurement group_id="B3" value="5.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Cotinine</title>
          <population>4 participants had samples that were unable to be analyzed.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="269"/>
                    <count group_id="B2" value="267"/>
                    <count group_id="B3" value="536"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268.7" spread="160.2"/>
                    <measurement group_id="B2" value="283.0" spread="151.2"/>
                    <measurement group_id="B3" value="275.8" spread="155.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exhaled Carbon monoxide</title>
          <population>Exhaled carbon monoxide was added after the study began and was collected only on 411 of 540 participants.</population>
          <units>ppm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="202"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.8" spread="9.4"/>
                    <measurement group_id="B2" value="17.1" spread="10.5"/>
                    <measurement group_id="B3" value="16.4" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="2.6"/>
                    <measurement group_id="B2" value="7.9" spread="2.4"/>
                    <measurement group_id="B3" value="8.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerstrom Test for Nicotine Dependence- 6 item</title>
          <description>FTND assessed nicotine dependence: possible total score ranges from 0 to 10. 0 indicates minimum physical nicotine dependence and 10 indicates maximum physical nicotine dependence.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="1.7"/>
                    <measurement group_id="B2" value="3.3" spread="1.7"/>
                    <measurement group_id="B3" value="3.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to first cigarette,&lt; or = 30 minutes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoke Menthol Cigarettes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="228"/>
                    <measurement group_id="B3" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quit Attempts</title>
          <description>Number of 24-hour quit attempts made in the past year.</description>
          <units>Quit Attempts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="7.9"/>
                    <measurement group_id="B2" value="3.9" spread="7.4"/>
                    <measurement group_id="B3" value="3.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pharmacotherapy use during most recent quit attempt</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of first cigarette</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.5" spread="5.8"/>
                    <measurement group_id="B2" value="18.1" spread="7.3"/>
                    <measurement group_id="B3" value="17.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age started smoking regularly</title>
          <population>One participant declined to respond.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="269"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="539"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="6.7"/>
                    <measurement group_id="B2" value="21.3" spread="7.4"/>
                    <measurement group_id="B3" value="21.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Motivation Scale</title>
          <description>Motivation to quit smoking scale asking about how important it is to quit smoking in the next week. 1 item scale. Scale of 0 = not important and 10 = extremely important.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" spread="0.8"/>
                    <measurement group_id="B2" value="9.8" spread="0.7"/>
                    <measurement group_id="B3" value="9.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Confidence Scale</title>
          <description>Confidence to quit smoking scale asking about how confident you are that you could quit smoking completely in the next week. 1 item scale. Scale of 0 = not confident and 10 = extremely confident.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="2.1"/>
                    <measurement group_id="B2" value="7.8" spread="2.0"/>
                    <measurement group_id="B3" value="7.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoke-free household</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>California Tobacco Survey: Inhale deeply</title>
          <description>Question asks &quot;Which statement best describes how or whether you inhale?&quot; Response options include 'I inhale deeply into my chest', I inhale partly into my chest', I inhale as far back as my throat', 'I inhale back into my throat', 'I just puff, I don't really inhale'.
Reporting number of participants who answered 'I inhale deeply into my chest'.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="270"/>
                    <count group_id="B2" value="270"/>
                    <count group_id="B3" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months</title>
        <description>Salivary cotinine-verified smoking abstinence at 6 months. A cut point of 15 ng/ml was used to differentiate smokers from nonsmokers.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion Arm</title>
            <description>270 African American adults received bupropion (150mg bid) for 7 weeks in addition to health education counseling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>270 African American adults received placebo for 7 weeks in addition to health education counseling.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months</title>
          <description>Salivary cotinine-verified smoking abstinence at 6 months. A cut point of 15 ng/ml was used to differentiate smokers from nonsmokers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on our previous studies, sample size was determined a priori assuming a two-sided x2 test with a type I error rate of .05, a power of 80%, and a cotinine-verified abstinence rate of 15% in the placebo group and 25% in the bupropion SR group at week 26, with the assumption that those lost to follow-up would be imputed as smokers.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The x2 test was used to determine whether there was a difference between treatment groups (bupropion SR vs placebo) in verified 7-day point prevalence abstinence at week 26, imputing the missing participants as smokers.</non_inferiority_desc>
            <p_value>.23</p_value>
            <p_value_desc>All tests of statistical significance were two-sided, and all P values less than .05 were considered statistically significant.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
            <estimate_desc>Raw proportions were used to estimate the verified cessation rate in each group and corresponding odds ratio along with its 95% confidence interval .</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Slow and Fast Metabolizers by Metabolite Ratio</title>
        <description>Analyzed CYP2A6 by activity, called the nicotine metabolite ratio using a split between slow and fast metabolism at 0.31.
The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.
Blood samples were collected for 3HC/COT ratio at Week 0.</description>
        <time_frame>Weeks 0</time_frame>
        <population>This variant is related to nicotine metabolism and was collected from all study participants but not analyzed by study arm as it does not relate to the study medication. Data pre-specified to be collected and reported as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All study participants were African American adults and received either bupropion (150mg bid) for 7 weeks in addition to health education counseling or placebo for 7 weeks in addition to health education counseling.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Slow and Fast Metabolizers by Metabolite Ratio</title>
          <description>Analyzed CYP2A6 by activity, called the nicotine metabolite ratio using a split between slow and fast metabolism at 0.31.
The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.
Blood samples were collected for 3HC/COT ratio at Week 0.</description>
          <population>This variant is related to nicotine metabolism and was collected from all study participants but not analyzed by study arm as it does not relate to the study medication. Data pre-specified to be collected and reported as a single arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fast Metabolizers by Nicotine Metabolite Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slow Metabolizers by Nicotine Metabolite Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>This reflects Week 7.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>This reflects Week 7.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants for Each CYP2B6 Allele</title>
        <description>We genotyped CYP2B6 in 268 from the Bupropion arm as this polymorphism is related to bupropion metabolism.</description>
        <time_frame>Week 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion Arm</title>
            <description>270 African American adults received bupropion (150mg bid)for 7 weeks in addition to health education counseling.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants for Each CYP2B6 Allele</title>
          <description>We genotyped CYP2B6 in 268 from the Bupropion arm as this polymorphism is related to bupropion metabolism.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CYP2B6*4 Allele Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2B6*5 Allele Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2B6*6 Allele Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2B6*9 Allele Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2B6*16 Allele Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2B6*18 Allele Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2B6*22 Allele Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Analysis relied on examining quit rates using linear regression, where the hydroxybupropion was a significant predictor of smoking cessation. CYP2B6 genotype was not a direct significant predictor of cessation in either the placebo or bupropion arm.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.82</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Bupropion adherent individuals with higher hydroxybupropion levels were more likely to be abstinent at Weeks 3, 7 and 26 compared to individuals with lower hydroxybupropion levels.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Slow and Fast Metabolizers by Genotype</title>
        <description>Analyzed CYP2A6 by genotype. The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.
Slow metabolizers have any reduction or loss of function variant. Fast metabolizers are *1/*1 genotype by exclusion.</description>
        <time_frame>Week 0</time_frame>
        <population>This variant is related to nicotine metabolism and was collected from all study participants but not analyzed by study arm as it does not relate to the study medication. Data pre-specified to be collected and reported as a single arm. Blood was unable to be analyzed for CYP2A6 genotype for 6 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All study participants were African American adults and received either bupropion (150mg bid) for 7 weeks in addition to health education counseling or placebo for 7 weeks in addition to health education counseling.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Slow and Fast Metabolizers by Genotype</title>
          <description>Analyzed CYP2A6 by genotype. The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.
Slow metabolizers have any reduction or loss of function variant. Fast metabolizers are *1/*1 genotype by exclusion.</description>
          <population>This variant is related to nicotine metabolism and was collected from all study participants but not analyzed by study arm as it does not relate to the study medication. Data pre-specified to be collected and reported as a single arm. Blood was unable to be analyzed for CYP2A6 genotype for 6 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Slow Metabolizers by Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fast Metabolizers by Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bupropion Arm</title>
          <description>270 African American adults received bupropion (150mg bid) for 7 weeks in addition to health education counseling.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>270 African American adults received placebo for 7 weeks in addition to health education counseling.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>MIddle ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Upper extremity dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Acoustic nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Personality Change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Infection, Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="270"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="270"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="270"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Over half of the participants who expressed interest in this study were ineligible according to study protocol. The lack of assessment between standardized assessment points limited the ability to characterize the process of relapse.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lisa Sanderson Cox</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-2643</phone>
      <email>lcox@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

